Fluocinolone acetonide intravitreal implants in Vogt-Koyanagi-Harada disease.

Abstract

PURPOSE:

To describe the use of fluocinolone acetonide implants (Retisert) in Vogt-Koyanagi-Harada disease (VKH).

DESIGN:

Interventional case series.

METHODS:

Retrospective review of medical records.

RESULTS:

Two patients with VKH requiring high-dose systemic corticosteroid therapy to control their inflammation and bilateral serous retinal detachments received bilateral fluocinolone acetonide implants. Upon tapering of systemic corticosteroids, one patient had recurrent serous retinal detachments and the other patient's anterior chamber and vitreous inflammation returned.

CONCLUSIONS:

The authors' experience with fluocinolone acetonide implants in VKH has been mixed with an inability to fully taper off of systemic corticosteroids.

• Authors: Yousuf Khalifa, Allison R Loh, Nisha R Acharya
• Journal: Ocular immunology and inflammation (Ocul Immunol Inflamm) 2009 Nov-Dec Vol. 17 Issue 6 Pg. 431-3 ISSN: 1744-5078 [Electronic] England
• PMID: 20001265 (Publication Type: Case Reports, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)

Chemical References

• Drug Implants
• Glucocorticoids
• Fluocinolone Acetonide
• Prednisone

Topics

• Administration, Oral
• Dose-Response Relationship, Drug
• Drug Administration Schedule
• Drug Implants
• Drug Therapy, Combination
• Female
• Fluocinolone Acetonide (administration & dosage)
• Glucocorticoids (administration & dosage)
• Humans
• Injections, Intravenous
• Male
• Prednisone (administration & dosage)
• Recurrence
• Retinal Detachment (complications, drug therapy)
• Retrospective Studies
• Treatment Outcome
• Uveomeningoencephalitic Syndrome (complications, drug therapy)
• Vitreous Body
• Young Adult